Condition (MeSH)
Esophageal Motility Disorders
ClinicalTrials.gov lists 1,397 trials for Esophageal Motility Disorders or a narrower condition beneath it. AstraZeneca has the most among industry and government lead sponsors, with 91.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
35 of the 1,397 trials are tagged with Esophageal Motility Disorders itself; the rest are tagged with a narrower condition beneath it.
When did Esophageal Motility Disorders trials start? (32)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 77
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 53 |
| 2025 | 70 |
| 2024 | 58 |
| 2023 | 66 |
| 2022 | 69 |
| 2021 | 66 |
| 2020 | 51 |
| 2019 | 54 |
| 2018 | 56 |
| 2017 | 60 |
Showing 10 of 32 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 66 trials starting in 2026 and about 65 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 80 trials still running at the 2026-10-09 snapshot; registered median of 21 months across 834 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Esophageal Motility Disorders trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 83 |
| Phase 1/2 | 12 |
| Phase 2 | 72 |
| Phase 2/3 | 17 |
| Phase 3 | 120 |
| Phase 4 | 135 |
| Not applicable | 544 |
| Observational | 412 |
| Expanded access | 2 |
How many Esophageal Motility Disorders trials are recruiting? (10)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 54 |
| Recruiting | 132 |
| Enrolling by invitation | 18 |
| Active, not recruiting | 33 |
| Completed | 784 |
Showing 5 of 10 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Esophageal Motility Disorders trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| AstraZeneca | 91 |
| Takeda | 31 |
| Chong Kun Dang Pharmaceutical | 10 |
| Edwards Lifesciences | 8 |
Which drugs are being tested for Esophageal Motility Disorders? (7)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| E3810 | 43 |
| Omeprazole 20 mg | 36 |
| Magnesium Pantoprazole | 31 |
| Lesogaberan | 10 |
| BLI5100 | 9 |
Showing 5 of 7 drugs.
Interventions as named in the registry (8)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Nexium Pill | 95 |
| lansoprazole OD | 29 |
| Dexlansoprazole MR | 25 |
| Vonoparazan | 13 |
| PPI | 9 |
Showing 5 of 8 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Esophageal Motility Disorders trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Heart Failure | 102 | 1 |
| Arrhythmia | 95 | 4 |
| Anemia | 87 | 3 |
| Pleural Effusion | 78 | 3 |
| Breathing abnormalities | 77 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Esophageal Motility Disorders? (86)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Gastrointestinal dysmotility is associated with proton pump inhibitor refractory oesophagitis in patients with systemic sclerosis. | Rheumatology (Oxford, England) | 2025 | Yes |
| Prospective Evaluation of Opioid Cessation in Patients With Suspected Opioid-Induced Esophageal Dysfunction. | The American journal of gastroenterology | 2025 | Yes |
| Esophageal motility disorders after COVID-19 infection. | Scientific reports | 2025 | Yes |
| Dysphagia associated with esophageal wall thickening in patients with nonspecific high-resolution manometry findings: Understanding motility beyond the Chicago classification version 4.0. | Neurogastroenterology and motility | 2024 | Yes |
| Functional Lumen Imaging Probe Panometry Helps Identify Clinically Relevant Esophagogastric Junction Outflow Obstruction per Chicago Classification v4.0. | The American journal of gastroenterology | 2023 | Yes |
Showing 5 of 86 publications.
Sub-conditions in MeSH (4)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.